Solid Biosciences

company

About

Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.

  • 101 - 250

Details

Last Funding Type
Seed
Industries
Biotechnology,Genetics,Health Care,Medical
Founded date
Jan 1, 2014
Number Of Employee
101 - 250
Operating Status
Active

Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Solid Biosciences has raised a total of — in funding over 2 rounds. Their latest funding was raised on Jan 31, 2014 from a Seed round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 31, 2014 Seed 1 JP Morgan Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Solid Biosciences is funded by 1 investors. JP Morgan are the most recent investors.
Investor Name Lead Investor Funding Round
JP Morgan Yes Seed